Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

Thrombosis and Haemostasis

Volumn 80, Issue 3, 1998, Pages 370-371

  Keularts, I M L W ^a   Beguin S ^a   De Zwaan, C ^b   Hemker, H C ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; PHOSPHOLIPID; PROCOAGULANT; THROMBIN; TIROFIBAN;

ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE RICH PLASMA;

EID: 0031757773     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615213     Document Type: Article

References (12)

1. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet mediated tissue induced thrombin generation by mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "Clinical Restenosis". J Clin Invest 1996; 98: 863-74.
2. Pedicord DL, Mousa SA, Dicker IB. Platelet GPIIb/IIIa antagonists inhibit platelet procoagulant activity. Thromb Haemost, Supplement 1997, p. 660, Abstract PS-2693.
3. Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR121566A, a potent GPIIb/IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998; 79: 383-8.
4. Gould RJ, Chang CTC, Lynch RJ, et al. MK-0383 is a potent non-peptide mimic of RGD that inhibits glycoprotein IIb/IIIa. Thromb Haemost 1993: 69: 976.
5. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol & Ther 1994; 56: 377-88
6. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
7. Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in PRP, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
8. Wagenvoord RJ, Hendrix HH, Hu Kai, Hemker HC. A chromogenic test to determine the procoagulant phospholipids in platelet rich plasma and whole blood. Thromb Haemost 1994; 72: 582-7.
9. Bevers EM, Comfurius P, van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
10. Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation whole blood - The effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
11. Sixty-Plus Reinfarction Study Research Group. A double blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-94.
12. Neri-Serneri GG, Rovelli F, Gensine GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 25: 937-42.